Andreia Gameiro

Lisbon, 1300477, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma.

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma.

Journal: Cancers
Published: December 22, 2022

The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications.

The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications.

Journal: Cells
Published: July 12, 2022

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.

Journal: Cancers
Published: September 21, 2021

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Journal: Cancers
Published: March 03, 2021

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.

Journal: Pharmaceutics
Published: February 16, 2021

Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.

Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.

Journal: Animals : an open access journal from MDPI
Published: December 08, 2020

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma.

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma.

Journal: Cancers
Published: November 29, 2020

Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.

Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.

Journal: Frontiers in veterinary science
Published: November 02, 2020

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.

Journal: Cancers
Published: April 16, 2020

CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.

CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.

Journal: BMC cancer
Published: January 18, 2018

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.

Journal: Oncotarget
Published: September 28, 2015

Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator.

Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator.

Journal: Lab on a chip
Published: August 29, 2014
Showing 1-12 of 12

Last Updated: 09/26/2026